Endometriosis is a non-cancerous disorder that occurs when tissue lining the inside of the uterus, known as the endometrium, appears in other parts of the body. It usually is found in the lower abdomen or pelvis but can appear in virtually any organ or tissue. Endometrial cancer, by contrast, occurs when cells in the endometrium … Read more
On the strength of the results of a major international clinical trial, there is now a new standard of care for patients with an advanced form of ovarian cancer who have responded to initial chemotherapy. The trial, dubbed SOLO-1, found that these patients – newly diagnosed with ovarian cancer that carries a mutation in the … Read more
A new generation of drugs and drug combinations is changing the outlook for patients with endometrial cancer. The results of the first clinical trials of the new therapies were so promising that they’ve led researchers to launch follow-up trials to explore the potential for even better outcomes. The trials are geared to patients diagnosed with … Read more
Endometrial cancer — sometimes referred to as uterine cancer — is the most common cancer of the female reproductive organs. In the case of this disease, malignant (cancerous) cells form in the endometrium. The endometrium is the lining of the uterus, an organ where a fetus grows. It mainly affecting postmenopausal women. With early detection, … Read more
It may not be sporting to hit someone when they’re down, but when the foe is a cancer cell, there’s no merit in mercy. That’s the principle behind drugs known as PARP inhibitors. Tumor cells that lack effective BRCA genes have difficulty repairing certain kinds of DNA damage, potentially leaving them vulnerable to agents that … Read more
Tests on living “organoids” created from patients’ ovarian cancer cells proved more accurate than DNA sequencing in predicting tumors’ sensitivity or resistance to chemotherapy drugs – and combining the two methods worked even better, say scientists at Dana-Farber Cancer Institute. The investigators report in Cancer Discovery that ovarian cancer organoids – tiny, three-dimensional spheres of cells … Read more
When Fran Austin’s ovarian cancer recurred after two rounds of chemotherapy, she found herself looking for a silver lining to the dark cloud of her disease. And she found it: Genetic profiling of her tumor identified her as an ideal candidate for an immunotherapy clinical trial, which has since shrunk her tumor by 60 percent … Read more
After two relapses, Janet Sheehan went on a clinical trial for her ovarian cancer. Four months later, her newest tumors were completely gone—and today, she’s relishing in a growing list of family milestones.
Julie Wisnia was undergoing treatment for ovarian cancer at Dana-Farber when she became inspired to participate in the Pan-Mass Challenge (PMC), a 163-mile bike-a-thon that raises funds for Dana-Farber.
Radiation therapy, or radiotherapy, is often one component of treatment for gynecologic malignancies such as cervical, vaginal, and endometrial cancer.
Common infections, such as those that cause the common cold, do not cause cancer or make cancer more likely to occur. However, infections with specific types of viruses, bacteria, or parasites can increase an individual’s risk for certain kinds of cancer.
Mutations in BRCA genes are linked to hereditary ovarian cancer as well as breast cancer.
Researchers are applying the knowledge they’ve gained in previous clinical trials as they look into how immunotherapy might provide additional treatment options for patients with recurrent cervical cancer.
Whenever Joan Janssen meets fellow ovarian cancer patients, she shares words of wisdom that she’s gained from seven years of living with the disease. “This is a recurring disease; don’t be stunned if it comes back,” she tells them. “You fought it the first time. You can do it even better the next time.” Janssen … Read more
Ovarian cancer often goes undetected before it reaches more invasive stages, but there is one aspect of the disease that frequently remains ignored even after diagnosis: Its impact upon a patient’s sexual health and function. Now, as research and treatment advances are allowing more women to live longer and healthier with ovarian cancer, Dana-Farber is … Read more
Although she had been fully prepped on what to expect, Barbara Losordo was a bit surprised at the ease and speed of her recovery from surgery for endometrial cancer. Discharged from the hospital the same day she had undergone the procedure, she needed no pain medication afterward. Within a week, she was driving. Within a month, … Read more
For women who inherit a breast and ovarian cancer susceptibility gene like mutant BRCA-1 or BRCA-2, the risk of ovarian and tubal cancers begins to rise significantly at age 40 to 45. Women at this age — and younger — are often advised to have their ovaries and tubes removed as a risk-reducing strategy for … Read more
By Linda Dzobiek I have been living with ovarian cancer for 13 years. I was diagnosed at age 53 with Stage 3C ovarian cancer, and after receiving care near my home in Providence, Rhode Island, my doctor referred me to Dana-Farber’s Susan F. Smith Center for Women’s Cancers for a clinical trial. I have been … Read more
By Mal Malme Each year during my annual checkup with my wonderful oncologist Panos A. Konstantinopoulos, MD, PhD, at the Susan F. Smith Center for Women’s Cancers at Dana-Farber, I reflect back on how grateful I am that my ovarian cancer is in remission. And while I appreciate the warmth and clinical expertise that he … Read more
By Ursula Matulonis, MD, Chief, Division of Gynecologic Oncology Immunotherapy, which has revolutionized the treatment of many types of cancer, is undergoing extensive study in patients with ovarian cancer. Although much of this research is in the early stages, it has produced some intriguing findings about the promise of this approach to treatment. Clinical trials … Read more